Table 2.

Clinical-Pathological Parameters of the Study Cohorts for Immunohistochemistry

	ccRCC	pRCC	chRCC	sRCC	RO	normal
	n = 141 (%)	n = 29 (%)	n = 10 (%)	n = 11 (%)	n = 10 (%)	n = 30 (%)
Sex
Male	88 (62.4)	26 (89.6)	6 (60.0)	7 (63.6)	0	21 (70.0)
Female	53 (37.6)	3 (10.3)	4 (40.0)	3 (27.3)	10 (100)	9 (30.0)
Age
Mean	62,11	61,45	63,2	62,1	57,6	57,93
Min–max	26–85	35–82	27–85	51–75	26–73	28–80
Pathological stage
pT1	59 (41.8)	19 (65.5)	6 (60.0)	0	n.a.	n.a.
pT2	31 (22.0)	5 (17.2)	4 (40.0)	1 (9.1)	n.a.	n.a.
pT3	49 (34.8)	5 (17.2)	0	8 (72.7)	n.a.	n.a.
pT4	2 (1.4)	0	0	1 (9.1)	n.a.	n.a.
Vascular invasion	43 (30.5)	0	0	8 (72.7)	n.a.	n.a.
LN metastasis	8 (5.7)	1 (3.4)	0	5 (45.5)	n.a.	n.a.
Distant metastasis	18 (12.8)	3 (10.3)	0	6 (54.5)	n.a.	n.a.
Grading
Grade 1	44 (31.2)	11 (37.9)	3 (30.0)	0	n.a.	n.a.
Grade 2	94 (66.7)	16 (55.1)	7 (70.0)	1 (9.1)	n.a.	n.a.
Grade 3	3 (2.1)	2 (6.9)	0	7 (63.6)	n.a.	n.a.
Grade 4	0	0	0	2 (18.2)	n.a.	n.a.

RO, renal oncocytoma; LN, Lymph node; n.a., not applicable.